Skip to Content
Global News Select

AstraZeneca, Daiichi Sankyo's Enhertu Gets Approval in EU For Lung Cancer Treatment

By Michael Susin


AstraZeneca said that its drug Enhertu, which it developed in partnership with Daiichi Sankyo, has been approved in the European Union for the treatment of advanced non-small cell lung cancer.

The Anglo-Swedish pharma giant on Monday said that it will receive $75 million from Daiichi as a milestone payment.

AstraZeneca added that the approval comes after positive clinical trial data.

The company added that sales of Enhertu in most of the E.U. territories are recognised by its partner.


Write to Michael Susin at


(END) Dow Jones Newswires

October 23, 2023 02:34 ET (06:34 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.

Market Updates

Sponsor Center